Next Article in Journal
The Natural Course of Non-Alcoholic Fatty Liver Disease
Previous Article in Journal
Polymeric Nanoparticle-Based Photodynamic Therapy for Chronic Periodontitis in Vivo
Article

Development of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed Mutagenesis

School of Life Science and Technology, China Pharmaceutical University, No. 24, Tong Jia Xiang, Nanjing 210009, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this paper.
Academic Editor: Terrence Piva
Int. J. Mol. Sci. 2016, 17(5), 764; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17050764
Received: 30 March 2016 / Revised: 1 May 2016 / Accepted: 6 May 2016 / Published: 20 May 2016
(This article belongs to the Section Biochemistry)
The activity of urate oxidase was lost during hominoid evolution, resulting in high susceptibility to hyperuricemia and gout in humans. In order to develop a more “human-like” uricase for therapeutic use, exon replacement/restoration and site-directed mutagenesis were performed to obtain porcine–human uricase with higher homology to deduced human uricase (dHU) and increased uricolytic activity. In an exon replacement study, substitution of exon 6 in wild porcine uricase (wPU) gene with corresponding exon in dhu totally abolished its activity. Substitutions of exon 5, 3, and 1–2 led to 85%, 60%, and 45% loss of activity, respectively. However, replacement of exon 4 and 7–8 did not significantly change the enzyme activity. When exon 5, 6, and 3 in dhu were replaced by their counterparts in wpu, the resulting chimera H1-2P3H4P5-6H7-8 was active, but only about 28% of wPU. Multiple sequence alignment and homology modeling predicted that mutations of E24D and E83G in H1-2P3H4P5-6H7-8 were favorable for further increase of its activity. After site-directed mutagenesis, H1-2P3H4P5-6H7-8 (E24D & E83G) with increased homology (91.45%) with dHU and higher activity and catalytic efficiency than the FDA-approved porcine–baboon chimera (PBC) was obtained. It showed optimum activity at pH 8.5 and 35 °C and was stable in a pH range of 6.5–11.0 and temperature range of 20–40 °C. View Full-Text
Keywords: uricase; exon replacement/restoration; site-directed mutagenesis uricase; exon replacement/restoration; site-directed mutagenesis
Show Figures

Graphical abstract

MDPI and ACS Style

Xie, G.; Yang, W.; Chen, J.; Li, M.; Jiang, N.; Zhao, B.; Chen, S.; Wang, M.; Chen, J. Development of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed Mutagenesis. Int. J. Mol. Sci. 2016, 17, 764. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17050764

AMA Style

Xie G, Yang W, Chen J, Li M, Jiang N, Zhao B, Chen S, Wang M, Chen J. Development of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed Mutagenesis. International Journal of Molecular Sciences. 2016; 17(5):764. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17050764

Chicago/Turabian Style

Xie, Guangrong; Yang, Weizhen; Chen, Jing; Li, Miaomiao; Jiang, Nan; Zhao, Baixue; Chen, Si; Wang, Min; Chen, Jianhua. 2016. "Development of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed Mutagenesis" Int. J. Mol. Sci. 17, no. 5: 764. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17050764

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop